Most patients experience minimal to no adverse effects
Neoepitopes were identified in DS and DP semaglutide follow-ons, indicating potential immunogenicity
(E)-3-(1H-Indol-7-yl)acrylonitrile 168685-01-6 3,3,3-Trifluoro-2-(1-phenyl-ethylimino)-propionic acid ethyl ester 193140-69-1 1-(1,1-Dimethylethyl) (2S,3R)-3-[(methylthio)methyl]-1,2-pyrrolidinedicarboxylate 193538-93-1 2-Hydroxy-2,4-dimethylbenzofuran-3(2H)-one 372119-01-2 N-[2-(3-Methoxyphenyl)-2-methylpropyl]formamide 60812-47-7 6-Methoxy-4,4-dimethyl-1,2,3,4-tetrahydro-isoquinoline-1-one 60812-60-4 1-(2-Methylprop-2-en-1-yl)cyclopropan-1-ol 130536-36-6 6-[4-(3-Chlorophenyl)-1-piperazinyl]-3(2H)-pyridazinone 362661-30-1 2,3,4,5-Tetrahydro-7,8-dimethoxy-3-(methylsulfonyl)-1H-3-benzazepin-1-one 14256-81-6 5-Benzyloxy-1-methylindole-3-carboxaldehyde 58630-07-2 Chemsrc provides CAS#:874462-73-4 MSDS, density, melting point, boiling point, structure, etc
Zhao L and Pickering G